TEVA Stock Risk & Deep Value Analysis
Teva Pharmaceutical Industries Ltd
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About TEVA Stock
We analyzed Teva Pharmaceutical Industries Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TEVA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is TEVA Stock?
Overall Risk
Moderate
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
High
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for TEVA?
- ⚠
Unfavorable outcomes in ongoing or new litigation
- ⚠
Increased competitive pressure in generics, leading to price erosion
- ⚠
Clinical trial failures or regulatory setbacks for pipeline products
- ⚠
Macroeconomic headwinds impacting pharmaceutical demand or pricing
Unlock TEVA Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Teva Pharmaceutical Industries Ltd (TEVA) Do?
Market Cap
$36.59B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
33,892
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Visit Teva Pharmaceutical Industries Ltd WebsiteIs TEVA Stock Undervalued?
Unlock the full AI analysis for TEVA
Get the complete DVR score, risk analysis, and more
Is TEVA Financially Healthy?
P/E Ratio
52.28
Does TEVA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
3 Identified
Teva's narrow moat is derived from its intellectual property for specialty drugs, which provides temporary market exclusivity, and its vast scale and efficient operations in the generics sector. While these elements provide a competitive edge, the generics market faces constant pricing pressure and specialty patents eventually expire, limiting the moat's long-term durability.
Moat Erosion Risks
- •Patent expirations on key specialty products (e.g., Austedo, Ajovy)
- •Aggressive pricing pressure and increased competition in the generics market
- •Ongoing regulatory scrutiny and potential legal liabilities (e.g., antitrust, opioid litigations)
TEVA Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive TEVA Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated early May 2026)
- •Updates on Austedo and Ajovy sales performance
- •Progress on biosimilar pipeline filings or approvals
Medium-Term (6-18 months)
- •Further significant debt reduction milestones
- •Potential new specialty product launches in 2027
- •Resolution of any remaining major legal liabilities
Long-Term (18+ months)
- •Successful pivot towards a higher-margin specialty and biosimilar-focused portfolio
- •Strategic M&A to expand growth segments
- •Sustainable operational efficiency improvements
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for TEVA?
- ✓
Acceleration in sales growth for Austedo and Ajovy
- ✓
Significant improvements in the net debt to EBITDA ratio
- ✓
Successful progression and commercialization of new biosimilar or specialty pipeline assets
Bull Case Analysis
See what could go right with Premium
Compare TEVA to Similar Stocks
See how Teva Pharmaceutical Industries Ltd stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TEVA (Teva Pharmaceutical Industries Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.


